Francisco Lopera Selected Research

Francisco Lopera Research Topics

Disease

68	Alzheimer Disease (Alzheimer's Disease) 12/2022 - 08/2001
19	Cognitive Dysfunction 12/2022 - 12/2010
16	Dementia (Dementias) 12/2022 - 03/2011
5	Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder) 01/2020 - 01/2003
4	CADASIL 11/2022 - 05/2011
4	Disease Progression 01/2022 - 03/2011
4	Amyloid Plaque 01/2021 - 10/2010
3	Parkinson Disease (Parkinson's Disease) 09/2021 - 01/2017
3	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2020 - 02/2017
2	Cerebral Amyloid Angiopathy (Congophilic Angiopathy) 11/2022 - 01/2022
2	Tauopathies 02/2022 - 01/2019
2	Memory Disorders (Memory Loss) 01/2020 - 01/2017
2	Mental Disorders (Mental Disorder) 08/2019 - 07/2019
2	Mitochondrial Diseases (Mitochondrial Disease) 04/2014 - 03/2004
2	Atrophy 05/2013 - 01/2012
1	Arteriosclerosis 11/2022
1	Synucleinopathies 02/2022
1	Neuroinflammatory Diseases 02/2022
1	COVID-19 01/2022
1	Neurobehavioral Manifestations 01/2021
1	Agnosia (Visual Agnosia) 12/2020
1	Mobius Syndrome (Moebius Syndrome) 08/2020
1	Cardiovascular Diseases (Cardiovascular Disease) 01/2020
1	Amyloidosis 01/2018
1	Prodromal Symptoms 01/2017
1	Dyslipidemias (Dyslipidemia) 04/2016
1	Diabetes Mellitus 04/2016
1	Hypertension (High Blood Pressure) 04/2016
1	Ataxia (Dyssynergia) 04/2014
1	Vascular Dementia (Subcortical Arteriosclerotic Encephalopathy) 05/2011
1	Ischemic Stroke 05/2011
1	Asymptomatic Diseases 12/2010
1	Amyloid angiopathy 10/2010
1	Huntington Disease (Huntington's Disease) 01/2006
1	Hepatolenticular Degeneration (Wilson's Disease) 09/2004
1	Seizures (Absence Seizure) 07/2004
1	Hippocampal Sclerosis 07/2004
1	Epilepsy (Aura) 07/2004

Drug/Important Bio-Agent (IBA)

38	Presenilin-1IBA 12/2022 - 08/2001
18	Biomarkers (Surrogate Marker)IBA 01/2022 - 09/2011
16	Flavin-Adenine Dinucleotide (FAD)IBA 11/2022 - 08/2001
14	Amyloid (Amyloid Fibrils)IBA 12/2022 - 03/2008
7	Amyloid beta-PeptidesIBA 11/2022 - 10/2010
7	Apolipoproteins E (ApoE)IBA 01/2022 - 12/2012
5	Indicators and Reagents (Reagents)IBA 01/2022 - 04/2016
4	Biological ProductsIBA 01/2022 - 09/2011
3	ApolipoproteinsIBA 07/2017 - 08/2003
2	Peptides (Polypeptides)IBA 02/2022 - 03/2008
2	Apolipoprotein E3IBA 01/2022 - 11/2019
2	Retinaldehyde (Retinal)IBA 01/2021 - 01/2016
2	crenezumabIBA 01/2018 - 01/2018
2	EndostatinsIBA 01/2016 - 05/2011
1	Fibrinogen (Factor I)FDA Link 11/2022
1	LactoferrinIBA 01/2022
1	propylene diquat (PDQ(+))IBA 09/2021
1	Misoprostol (Cytotec)FDA LinkGeneric 08/2020
1	tau Proteins (tau Protein)IBA 01/2020
1	amyloid beta-protein (1-42)IBA 01/2020
1	amyloid beta-protein (1-38)IBA 01/2020
1	Cholinergic Agents (Cholinergics)IBA 01/2020
1	SphingolipidsIBA 01/2020
1	Pemetrexed (MTA)FDA Link 01/2020
1	Glucosylceramidase (Glucocerebrosidase)IBA 01/2019
1	7- (6- fluoropyridin- 3- yl)- 5H- pyrido(4,3- b)indoleIBA 01/2018
1	Phospholipids (Phosphatides)FDA LinkGeneric 01/2018
1	LipidsIBA 01/2018
1	2- (4'- (methylamino)phenyl)- 6- hydroxybenzothiazole (Pittsburgh compound B)IBA 01/2018
1	CarbonIBA 01/2018
1	Phosphotransferases (Kinase)IBA 01/2017
1	Leucine (L-Leucine)FDA Link 01/2017
1	Codon (Codons)IBA 01/2017
1	High-Temperature Requirement A Serine Peptidase 1IBA 01/2016
1	ProteomeIBA 01/2016
1	Proteins (Proteins, Gene)FDA Link 01/2016
1	LigandsIBA 01/2016
1	Cadherins (E-Cadherin)IBA 01/2016
1	CateninsIBA 01/2016
1	Delta CateninIBA 01/2016
1	Glucose (Dextrose)FDA LinkGeneric 03/2015
1	CalciumIBA 04/2014
1	florbetapirIBA 12/2012
1	Protons (Proton)IBA 12/2012
1	ClusterinIBA 05/2011
1	CollagenIBA 05/2011
1	Notch3 ReceptorIBA 05/2011
1	Protein Isoforms (Isoforms)IBA 10/2010
1	Peptide Hydrolases (Proteases)FDA Link 10/2010
1	Nicotinic Receptors (Nicotinic Acetylcholine Receptor)IBA 05/2009
1	Amyloid Precursor Protein Secretases (beta-Secretase)IBA 03/2008
1	CopperIBA 09/2004
1	P-type ATPasesIBA 09/2004
1	IronIBA 03/2004
1	Heat-Shock Proteins (Heat-Shock Protein)IBA 03/2004
1	Caspase 3 (Caspase-3)IBA 03/2004
1	NF-kappa B (NF-kB)IBA 03/2004
1	Dopamine (Intropin)FDA LinkGeneric 03/2004

Therapy/Procedure

4	Therapeutics 02/2022 - 01/2016
1	Combined Modality Therapy 01/2020
1	Immunotherapy 12/2016
1	Activities of Daily Living (ADL) 03/2011